Bioventus collaborates with MTF Biologics in tissue product for knee osteoarthritis

Written by Alan Condon | June 10, 2019 | Print  |

Bioventus has partnered with MTF Biologics to co-develop a placental tissue product for the treatment of painful musculoskeletal conditions, focusing initially on knee osteoarthritis.

Three things to know:

1. The collaboration hopes to develop a solution for knee osteoarthritis that provides symptom relief and delays progression of the disease.

2. Bioventus is an orthobiologics company that creates cost effective solutions for bone healing, bone graft and osteoarthritis.

3. MTF Biologics — also known as the Musculoskeletal Transplant Foundation — is a nonprofit tissue bank governed by a board of surgeons.

"There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body's natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues," said Tony Bihl, CEO of Bioventus.

More articles on biologics:
Dr. Selby Chen of the Mayo Clinic: The major challenges facing spine today
R3 Stem Cell responds to FDA's safety concerns — 3 insights
Judge grants FDA permission to regulate stem cell practice — 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers